Friday, July 25, 2014 Last update: Yesterday, 11:33 PM
FreshNews.com - All Company Technology News Since 1996

CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial O

Companies mentioned in this article: Cannabis Science, Inc.

COLORADO SPRINGS, Colo., July 18, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC:CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting bring attention to more evidence on the investor appetite to invest in quality companies.

This week, the Wall Street Journal wrote a commentary piece entitled "Pot Industry Puts a Tie On" where Chief Financial Officer of Cannabis Science, Inc. Robert Kane provides his economic insight on the industry and explains growth challenges this sector is going through as they mature into a larger market. A version of the entire article is available for viewing at the link below: http://mobile.blogs.wsj.com/cfo/2014/07/15/pot-industry-puts-on-a-tie/?mg=blogs-wsj

"Thank you to John Kester for bringing attention to this industry. To me this article is more evidence of the maturing investor appetite for the cannabis industry, seeking quality and investing in companies with strong executive management teams and quality advisory boards. There are challenges but I am honored to be a part of the team that overcomes every one of these challenges." Stated Robert Kane, CFO Cannabis Science.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824

Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

SOURCE Cannabis Science, Inc.